Please try another search
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children’s Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Name | Age | Since | Title |
---|---|---|---|
Maurice Zauderer | 75 | 2001 | Co-Founder, CEO, President & Director |
Albert D. Friedberg | 74 | 2001 | Chairman of the Board |
Bala S. Manian | 77 | 2004 | Independent Director |
Leisha A Emens | - | - | Scientific & Clinical Advisor |
Ramesh Ramanathan | - | - | Scientific & Clinical Advisor |
Max Vasquez | - | - | Member of Scientific & Clinical Advisory Board |
Amita Patnaik | - | - | Scientific & Clinical Advisor |
Laura J. Balcer | - | - | Scientific & Clinical Advisor |
Steven L. Galetta | - | - | Scientific & Clinical Advisor |
Charles Warren Olanow | - | - | Scientific & Clinical Advisor |
David M. Essayan | - | - | Scientific & Clinical Advisor |
Gerald E. Van Strydonck | 77 | 2003 | Independent Director |
Andrew Feigin | - | - | Scientific & Clinical Advisor |
Ray Dorsey | - | - | Scientific & Clinical Advisor |
Matilde Inglese | - | - | Scientific & Clinical Advisor |
Jacob B. Frieberg | 65 | 2015 | Independent Lead Director |
Susan Jerian | - | - | Scientific & Clinical Advisor |
Karl Kieburtz | - | - | Scientific Advisor |
Khurram Bashir | - | - | Scientific and Clinical Advisor |
Elizabeth M. Jaffe | - | - | Scientific & Clinical Advisor |
Mark J. Tullman | - | - | Scientific and Clinical Advisor |
Anthony W. Tolcher | - | - | Scientific and Clinical Advisor |
Jeffrey A. Cohen | - | - | Scientific & Clinical Advisor |
Peter A. Calabresi | - | - | Scientific & Clinical Advisor |
Andrew D. Goodman | - | - | Scientific & Clinical Advisor |
Barbara Yanni | 68 | 2015 | Independent Director |
Chrystyna Bedrij Stecyk | 59 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review